Pirtobrutinib in the Management of R/R CLL: Updates from the BRUIN Trial

Panelists discuss how the non-covalent BTK inhibitor pirtobrutinib has shown promising results in the BRUIN clinical trials for both BTK inhibitor-naive and previously treated chronic lymphocytic leukemia patients, reviewing key efficacy and safety data presented at recent hematology conferences.

EP: 1.The Current Treatment Landscape for R/R CLL

EP: 2.Impact of Prior BTKi vs BCL2i Therapy on Treatment Decision-Making in CLL

EP: 3.Key Patient-Specific Factors Guiding Treatment Selection in CLL

EP: 4.Tailoring Treatment Approaches for Rapid vs. Slow Disease Progression in CLL

EP: 5.Assessing Resistance to First-Line BTK Inhibitor Therapy: The Emergine Role of Testing in CLL

Now Viewing

EP: 6.Pirtobrutinib in the Management of R/R CLL: Updates from the BRUIN Trial

Video content above is prompted by the following:

• To briefly review the non-covalent BTKi pirtobrutinib and BRUIN data.
  • Pirtobrutinib (BRUIN) – BRUIN BTKi Naive EHA 2024; BRUIN prior BTKi

Related Videos